Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating)’s share price fell 2.2% on Friday after Barclays lowered their price target on the stock from $90.00 to $80.00. The company traded as low as $41.10 and last traded at $41.33. 56,135 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 553,478 shares. The stock had previously closed at $42.26.
A number of other equities research analysts have also weighed in on PCRX. BMO Capital Markets dropped their price target on Pacira BioSciences from $60.00 to $52.00 and set a “market perform” rating on the stock in a research note on Friday, January 6th. Royal Bank of Canada dropped their target price on shares of Pacira BioSciences from $80.00 to $76.00 and set an “outperform” rating on the stock in a research report on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 31st. Cowen dropped their price target on Pacira BioSciences from $54.00 to $50.00 in a research note on Wednesday, December 14th. Finally, HC Wainwright upped their price objective on shares of Pacira BioSciences from $69.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $64.36.
Institutional Investors Weigh In On Pacira BioSciences
Several hedge funds have recently modified their holdings of PCRX. Neo Ivy Capital Management acquired a new position in Pacira BioSciences in the 2nd quarter worth about $44,000. Financial Freedom LLC purchased a new stake in shares of Pacira BioSciences in the fourth quarter valued at approximately $33,000. Quadrant Capital Group LLC raised its stake in shares of Pacira BioSciences by 380.8% during the 3rd quarter. Quadrant Capital Group LLC now owns 875 shares of the company’s stock worth $47,000 after buying an additional 693 shares during the period. ICA Group Wealth Management LLC acquired a new position in shares of Pacira BioSciences during the 4th quarter worth approximately $35,000. Finally, Dark Forest Capital Management LP lifted its position in shares of Pacira BioSciences by 92,300.0% during the 4th quarter. Dark Forest Capital Management LP now owns 924 shares of the company’s stock valued at $36,000 after buying an additional 923 shares in the last quarter.
Pacira BioSciences Stock Down 3.0 %
The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 136.32 and a beta of 0.77. The business’s 50 day moving average is $39.57 and its 200-day moving average is $47.34. The company has a debt-to-equity ratio of 0.85, a quick ratio of 3.32 and a current ratio of 3.37.
Pacira BioSciences Company Profile
Pacira Biosciences, Inc is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.